Animal & Imaging Core Facility, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait.
Immunology & Microbiology, Dasman Diabetes Institute (DDI), Al-Soor Street, P.O. Box 1180, Dasman 15462, Kuwait.
Cells. 2020 Mar 16;9(3):730. doi: 10.3390/cells9030730.
Interferon regulatory factors (IRFs) are emerging as the metabolic transcriptional regulators in obesity/type-2 diabetes (T2D). IRF5 is implicated with macrophage polarization toward the inflammatory M1-phenotype, nonetheless, changes in the adipose expression of IRF5 in T2D and relationship of these changes with other markers of adipose inflammation remain unclear. Therefore, we determined the IRF5 gene expression in subcutaneous adipose tissue samples from 46 T2D patients including 35 obese (Body Mass Index/BMI 33.83 ± 0.42kg/m) and 11 lean/overweight individuals (BMI 27.55 ± 0.46kg/m) using real-time qRT-PCR. IRF5 protein expression was assessed using immunohistochemistry and confocal microscopy. Fasting plasma glucose, insulin, HbA1c, C-reactive protein, cholesterol, low- and high-density lipoproteins (LDL/HDL), and triglycerides were measured using commercial kits. IRF5 gene expression was compared with that of signature inflammatory markers and several clinico-metabolic indicators. The data (mean ± SEM) show the enhanced adipose IRF5 gene ( = 0.03) and protein ( = 0.05) expression in obese compared to lean/overweight diabetic patients. Adipose IRF5 transcripts in diabetic obese individuals associated positively with those of TNF-α, IL-18, IL-23A, CXCL8, CCL2, CCL7, CCR1/5, CD11c, CD68, CD86, TLR4/7/10, Dectin-1, FGL-2, MyD88, NF-κB, IRF3, and AML1 (p < 0.05). In diabetic lean/overweight subjects, IRF5 expression associated with BMI, body fat %age, glucose, insulin, homeostatic model assessment of insulin resistance (HOMA-IR, C-reactive protein (CRP), IL-5, and IL-1RL1 expression; while in all T2D patients, IRF5 expression correlated with that of IRF4, TLR2/8, and CD163. In conclusion, upregulated adipose tissue IRF5 expression in diabetic obese patients concurs with the inflammatory signatures and it may represent a potential marker for metabolic inflammation in obesity/T2D.
干扰素调节因子 (IRFs) 作为代谢转录调节剂在肥胖/2 型糖尿病 (T2D) 中逐渐受到关注。IRF5 与巨噬细胞向炎症 M1 表型极化有关,然而,T2D 患者脂肪组织中 IRF5 的表达变化及其与脂肪组织炎症其他标志物的关系尚不清楚。因此,我们使用实时 qRT-PCR 测定了 46 例 T2D 患者(包括 35 例肥胖者 [体重指数 (BMI)/33.83 ± 0.42kg/m] 和 11 例瘦/超重者 [BMI 27.55 ± 0.46kg/m])皮下脂肪组织样本中的 IRF5 基因表达。使用免疫组织化学和共聚焦显微镜评估 IRF5 蛋白表达。使用商业试剂盒测量空腹血糖、胰岛素、HbA1c、C 反应蛋白、胆固醇、低和高密度脂蛋白 (LDL/HDL)、和甘油三酯。将 IRF5 基因表达与特征性炎症标志物和几种临床代谢指标进行比较。数据(平均值 ± SEM)显示,与瘦/超重的糖尿病患者相比,肥胖患者的脂肪组织中 IRF5 基因( = 0.03)和蛋白( = 0.05)表达增强。糖尿病肥胖个体的脂肪组织 IRF5 转录物与 TNF-α、IL-18、IL-23A、CXCL8、CCL2、CCL7、CCR1/5、CD11c、CD68、CD86、TLR4/7/10、Dectin-1、FGL-2、MyD88、NF-κB、IRF3 和 AML1 的转录物呈正相关(p < 0.05)。在糖尿病瘦/超重患者中,IRF5 表达与 BMI、体脂肪百分比、血糖、胰岛素、胰岛素抵抗稳态模型评估值 (HOMA-IR)、C 反应蛋白 (CRP)、IL-5 和 IL-1RL1 表达相关;而在所有 T2D 患者中,IRF5 表达与 IRF4、TLR2/8 和 CD163 表达相关。总之,糖尿病肥胖患者脂肪组织中 IRF5 表达上调与炎症特征一致,可能代表肥胖症/T2D 代谢炎症的潜在标志物。